Otsuka Holdings Co., Ltd.

Cullinan Therapeutics and Taiho have a significant market opportunity with zipalertinib after successful results in the Phase I/II REZILIENT1 trial among previously treated non-small cell lung cancer

The US Food and Drug Administration is in the early phases of reconsidering the long-standing class-wide “black box” warning for antipsychotics citing increased mortality in older adults with dementia

With Spravato (esketamine) showing signs of solid growth during its fifth year on the market in 2024, Johnson & Johnson got another sign of confidence for the treatment-resistant depression drug o

With now three drugs for immunoglobulin A nephropathy (IgAN) having US Food and Drug Administration approval, the disease has become a competitive space, one into which Otsuka Pharmaceutical Co. Ltd.